5 Key Takeaways

• 1

  Photobiomodulation (PBM) for intermediate dry AMD received FDA authorization in November 2024, offering a new treatment option beyond traditional methods.

• 2

  PBM is performed in a clinical setting without anesthesia, unlike intravitreal injections, and has shown potential to improve visual function.

• 3

  Medicare does not reimburse hospital facility fees for PBM, and state laws define the roles of healthcare workers involved in its administration.

• 4

  CPT code 0936T was introduced for PBM, but other codes related to laser therapy cannot be used, as PBM does not involve laser technology.

• 5

  Claims for PBM performed by qualified health professionals are reimbursed at 100% under Medicare if they meet 'incident to' service conditions.